Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhNGF eye drops in dry eye
NCT03019627Phase 2Completed
- Sponsor
- Dompé
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry eye syndrome (DED) comparing rhNGF 20μg/mL with Vehicle (2 arms). Primary endpoint: Symptom Assessment in Dry Eye Scores at 8 weeks. Started Jan 2017; status: completed.
02
Drugs
cenegermin
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03019627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019627.